Rational use of biological response modifiers in hematological malignancies--a review of treatment with interferon, cytotoxic cells and antibodies.

Leukemia Research
C H JansonH Mellstedt

Abstract

During the last decade the use of various biologic therapeutics/biological response modifiers in hematological malignancies has increased dramatically. Alpha-interferon (alpha-IFN) alone has clearly a substantial antitumoral effect in many hematological diseases. During the coming decade an improved effect will probably be seen by combination of alpha-IFN with cytostatics and other biologic therapeutics as well as by finding the optimal conditions when alpha-IFN should be used. Using unconjugated mouse monoclonal antibodies (MAb) only, an overall response rate of 38% was noted in patients with advanced disease. MAb therapy might be improved by using other Ig molecules, combination with cytokines and by finding an optimal dosage schedule. Only a few patients with hematological malignancies have been treated with IL-2/LAK cells. An overall response rate of 41% was seen in heavily pretreated patients. In all biologic therapeutics, an improved efficacy will be noted if patients with a low tumor burden and an intact immune system are treated. Immunization/vaccination with "tumor antigen" will probably contribute to an improved prognosis, especially in patients with minimal residual disease. There are several good candidates to be us...Continue Reading

References

Feb 1, 1988·The Journal of Experimental Medicine·A LanzavecchiaG Moldenhauer
Oct 1, 1989·Scandinavian Journal of Immunology·M AnderssonH Mellstedt
Apr 1, 1988·Hematological Oncology·H Mellstedt
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D HerlynM Scriba
Sep 9, 1982·The New England Journal of Medicine·K A Foon

❮ Previous
Next ❯

Citations

Mar 1, 1993·The American Journal of Medicine·D M Goldenberg
Jul 1, 1994·São Paulo Medical Journal = Revista Paulista De Medicina·F M GrippA Rapoport
Mar 1, 1995·Cancer Immunology, Immunotherapy : CII·R H BrakenhoffG A van Dongen
Jan 1, 1993·Medical Oncology and Tumor Pharmacotherapy·C H Janson

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.